Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Closes C$1.6M Private Placement

NEW YORK (GenomeWeb) – GeneNews announced today that it has closed a C$1.6 million ($1.2 million) private placement of stock and warrants.

The placement consisted of about 9.8 million units comprising one common share and one quarter of a warrant for the purchase of one share. A full warrant entitles the holder to buy a share of GeneNews at C$.50 by Aug. 15, 2018.

About 5.1 million of the units were sold to new investors, with 2.5 million units used to retire approximately C$400,000 in debt owed to a major shareholder and company director, GeneNews said. Additionally, 600,000 units were provided in lieu of a C$100,000 cash payment for services rendered by a company director.

GeneNews said it plans to use the proceeds of the private placement — which comes about three month after the firm secured a C$5 million capital commitment from Global Emerging Markets Global Yield Fund — for product commercialization, working capital, and general corporate purposes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.